Get the Stockscreener App
2.74
3.40%
0.09
Ventyx Biosciences Inc stock is traded at $2.74, with a volume of 462.03K.
It is up +3.40% in the last 24 hours and down -9.27% over the past month.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
See More
Previous Close:
$2.65
Open:
$2.69
24h Volume:
462.03K
Relative Volume:
0.30
Market Cap:
$195.39M
Revenue:
-
Net Income/Loss:
$-192.96M
P/E Ratio:
-0.8303
EPS:
-3.3
Net Cash Flow:
$-167.04M
1W Performance:
-3.18%
1M Performance:
-9.27%
6M Performance:
+70.19%
1Y Performance:
+39.09%
1-Day Range:
$2.68
$2.809
1-Week Range:
$2.38
$2.915
52-Week Range:
$0.783
$3.39
Ventyx Biosciences Inc Stock (VTYX) Company Profile
Name
Ventyx Biosciences Inc
Sector
Industry
Phone
(858) 945-2393
Address
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Compare VTYX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
2.74 | 201.80M | 0 | -192.96M | -167.04M | -3.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Mar-12-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-07-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-07-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-07-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-07-23 | Downgrade | Stifel | Buy → Hold |
| Nov-07-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Wells Fargo | Overweight |
| Dec-19-22 | Initiated | Goldman | Buy |
| Nov-17-22 | Initiated | Morgan Stanley | Overweight |
| Sep-07-22 | Initiated | Stifel | Buy |
| Sep-01-22 | Initiated | H.C. Wainwright | Buy |
| May-09-22 | Initiated | Credit Suisse | Outperform |
| Mar-31-22 | Initiated | Canaccord Genuity | Buy |
| Feb-01-22 | Initiated | Oppenheimer | Outperform |
| Nov-15-21 | Initiated | Jefferies | Buy |
| Nov-15-21 | Initiated | Piper Sandler | Overweight |
View All
Ventyx Biosciences Inc Stock (VTYX) Latest News
Are Bears Losing Grip on Ventyx Biosciences Inc.Gap Down & Safe Entry Point Identification - classian.co.kr
Technical analysis overview for Ventyx Biosciences Inc. stockWeekly Trade Review & Daily Oversold Stock Bounce Ideas - Newser
Ventyx Biosciences Inc. stock prediction for this week2025 EndofYear Setup & Community Consensus Trade Alerts - Newser
Heatmap analysis for Ventyx Biosciences Inc. and competitorsWeekly Risk Summary & Reliable Volume Spike Trade Alerts - Newser
Risk adjusted return profile for Ventyx Biosciences Inc. analyzedMarket Volume Summary & Stepwise Entry/Exit Trade Alerts - Newser
What MACD and RSI say about Ventyx Biosciences Inc.Recession Risk & Low Risk Entry Point Tips - Newser
How to use Fibonacci retracement on Ventyx Biosciences Inc.Market Sentiment Review & Weekly Return Optimization Plans - Newser
Leading vs lagging indicators on Ventyx Biosciences Inc. performanceJuly 2025 WrapUp & Daily Profit Focused Stock Screening - Newser
How institutional ownership impacts Ventyx Biosciences Inc. stockSwing Trade & Community Verified Trade Alerts - Newser
What machine learning models say about Ventyx Biosciences Inc.July 2025 Earnings & Trade Opportunity Analysis Reports - Newser
Published on: 2025-08-20 15:11:24 - classian.co.kr
Custom strategy builders for tracking Ventyx Biosciences Inc.Quarterly Market Review & Weekly Return Optimization Plans - Newser
Should you wait for a breakout in Ventyx Biosciences Inc.2025 Volume Leaders & Technical Confirmation Trade Alerts - Newser
Will Ventyx Biosciences Inc. stock go up soonJuly 2025 Setups & Entry and Exit Point Strategies - Newser
Is Ventyx Biosciences Inc. forming a bottoming baseFed Meeting & Capital Protection Trading Alerts - Newser
Real time scanner hits for Ventyx Biosciences Inc. explainedWeekly Trend Report & Weekly Top Gainers Alerts - Newser
Top chart patterns to watch in Ventyx Biosciences Inc.July 2025 Opening Moves & Entry and Exit Point Strategies - Newser
Ventyx Biosciences Inc. stock outlook for YEARJuly 2025 Chart Watch & Daily Market Momentum Tracking - Newser
Building trade automation scripts for Ventyx Biosciences Inc.Trade Volume Report & Long-Term Safe Investment Ideas - Newser
Ventyx Biosciences Reports Decreased Losses in 2025 - MSN
Smart tools for monitoring Ventyx Biosciences Inc.’s price actionJuly 2025 Setups & Safe Capital Growth Stock Tips - Newser
What makes Ventyx Biosciences Inc. stock price move sharplyEarnings Miss & AI Powered Trade Plan Recommendations - thegnnews.com
Will Ventyx Biosciences Inc. outperform the market in YEAR2025 Earnings Surprises & Stock Portfolio Risk Management - thegnnews.com
XTX Topco Ltd Sells 50,472 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Full technical analysis of Ventyx Biosciences Inc. stockPortfolio Risk Report & Weekly Chart Analysis and Trade Guides - Newser
Ventyx Biosciences Reports Q2 2025 Earnings: Decreased Losses and Improved Cash Position - AInvest
What MACD signals say about Ventyx Biosciences Inc.2025 Market WrapUp & Verified Momentum Stock Watchlist - Newser
Can Ventyx Biosciences Inc. lead its sector in growthJuly 2025 Update & Free Technical Pattern Based Buy Signals - 선데이타임즈
Is Ventyx Biosciences Inc. the Top Chart Pick This WeekTrade Performance Summary & Free Community Supported Trade Ideas - sundaytimes.kr
What recovery options are there for Ventyx Biosciences Inc.Earnings Summary Report & Real-Time Sentiment Analysis - Newser
Will Ventyx Biosciences Inc. rebound enough to break evenQuarterly Earnings Summary & Real-Time Volume Surge Alerts - Newser
Ventyx Biosciences Inc. Stock Approaches Key Moving AverageWeekly Market Summary & Entry Point Confirmation Alerts - beatles.ru
Tools to monitor Ventyx Biosciences Inc. recovery probabilityWeekly Volume Report & Daily Price Action Insights - Newser
Ventyx Biosciences Inc. stock chart pattern explainedVolume Spike & Community Verified Swing Trade Signals - Newser
Published on: 2025-08-12 23:04:56 - Newser
Has Ventyx Biosciences Inc. Stock Ever Crashed Historical Volatility ReviewValue Holding Return Summary With Outlook - Newser
What technical models suggest about Ventyx Biosciences Inc.’s comebackTrend Reversal & AI Forecast Swing Trade Picks - Newser
Trading Bots Trigger Alerts on Ventyx Biosciences Inc. ActivityFree Access to Investment Community - beatles.ru
Canaccord Genuity Keeps Their Buy Rating on Ventyx Biosciences (VTYX) - The Globe and Mail
Can Ventyx Biosciences Inc Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Detecting support and resistance levels for Ventyx Biosciences Inc.Weekly Outlook for Short Term Investors - Newser
Ventyx Biosciences Inc Stock (VTYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ventyx Biosciences Inc Stock (VTYX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mohan Raju | CEO AND PRESIDENT |
Mar 28 '25 |
Option Exercise |
0.00 |
11,844 |
0 |
2,303,540 |
| Nuss John | CHIEF SCIENTIFIC OFFICER |
Mar 28 '25 |
Option Exercise |
0.00 |
4,531 |
0 |
469,113 |
| Nuss John | CHIEF SCIENTIFIC OFFICER |
Dec 27 '24 |
Sale |
2.36 |
21,119 |
49,841 |
464,582 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):